Median Technologies Reports H1 2026 Financial Results and Q3 Business Highlights

Fredrik Brag, CEO and Founder of Median Technologies

“With the regulatory pathway secured for eyonis® LCS in the United States and Europe, our focus has shifted decisively to commercial execution. We enter this next phase from a position of financial strength and with the resources to execute our strategy. With our U.S. organization now in place, we are advancing the commercial rollout of eyonis® LCS and expect to generate first revenues in the first half of 2027. Our iCRO business delivered a record third quarter, with revenue reaching €6.7 million, up 14.4% compared with the third quarter of 2025. Year-to-date revenue is up 8% versus the same period in 2025, which will reflect in the full year performance. Strong commercial momentum continued, as the Company also secured one of the largest projects in its history, a €8.4 million global Phase III oncology imaging project. The order backlog reached a new record of €90.9 million at the end of September, providing solid visibility for future growth. Against this strong operational and financial backdrop, our Strategic Review Committee continues to assess the best path forward to fully realize the potential of our two businesses and maximize long-term value for our shareholders.”